Treatment of Social Phobia
Launched by BOSTON UNIVERSITY CHARLES RIVER CAMPUS · Nov 2, 1999
Trial Information
Current as of March 21, 2025
Completed
Keywords
ClinConnect Summary
The primary goal of the present study is to identify the mediators and moderators of change in the treatment of social phobia and, in so doing suggest a common mechanism of action for all brief psychosocial interventions. Perceived self-efficacy of social behavior, negative cognitive appraisal (estimated social costs), and perceived emotional control will be considered as potential mediators; avoidant personality disorder and the generalized subtype of social phobia will be considered as potential predictors for poor treatment outcome.
Social phobia is a very prevalent and debilitating dis...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • -
- Patients must have:
- • Social phobia with public speaking anxiety.
Trial Officials
Stefan Hofmann, PhD
Principal Investigator
About Boston University Charles River Campus
Boston University Charles River Campus is a prominent academic institution dedicated to advancing health and science through innovative research and education. As a sponsor of clinical trials, the campus leverages its extensive resources and interdisciplinary expertise to facilitate groundbreaking studies that aim to improve patient outcomes and contribute to the understanding of various medical conditions. With a commitment to ethical research practices and collaboration with healthcare professionals, Boston University Charles River Campus plays a vital role in translating scientific discoveries into clinical applications that benefit communities locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials